Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

After years of disappointments, biotech stocks are on an unaccustomed run. The SPDR S&P Biotech ETF, which trades under the ticker XBI, is up around 20% since the start of September, and is ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

The European Union’s upcoming Biotech Act is hotly anticipated in the world of food. The Act could be integral to food innovation, streamlining regulation in areas such as precision fermentation. The ...

Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and scientific signals. Effective visualization enhances decision-making, ...